[{"orgOrder":0,"company":"JN Nova Pharma","sponsor":"Government of Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Canadian Biotech JN Nova Pharma Inc. Partners with the Government of Canada to Develop Therapeutic Platform for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"JN Nova Pharma","sponsor":"NRC Human Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JN Nova Pharma and NRC Human Health Group Partnership to Move Pan-COVID19 Therapeutic into Clinical Development, their lead therapeutic product JN2019 neutralizes the SARS-CoV-2 variants of concern (VOCs), including Omicron","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by JN Nova Pharma
JN2019 traps and inhibits viral entry to the lungs/airways via an enhanced ACE2 decoy, is capable of binding and neutralizing all SARS-CoV-2 variants of concern that have emerged throughout the pandemic.
The goal of this therapeutic platform is to both prevent SARS-Cov2 cellular invasion into these tissues (‘viral trap’) and to mitigate pathology triggered by the host response to the virus, including over-activation of immune system and lung and heart failure.